I’ve been watching the field’s obsession with senolytic clearance as the ultimate fix for tissue rejuvenation, but I’m starting to think we’re missing the forest for the trees. The prevailing view treats the senescent cell burden as a strictly pathological state that needs to be purged. Yet, if we look at the evolutionary logic—or the lack of it—it’s possible we’re just hacking away at a safety valve.

My lab has been running simulations on orthogonal metabolic circuits, and the data suggests these cells aren't just biological debris. Often, they’re running a desperate, if clumsy, homeostatic program to prevent neoplastic transformation in compromised tissues. By killing them off wholesale, we’re removing the signal, not the source of the dysregulation. We’re essentially treating the smoke while ignoring the electrical fire.

I’m increasingly convinced that the future lies in metabolic reprogramming, not selective apoptosis. Why kill a cell that’s entered terminal arrest if we can re-engineer its secretome instead? If we could swap an inflammatory SASP for a regenerative one—turning these cells into a temporary niche for repair rather than a source of chronic irritation—we’d likely bypass the fibrosis and functional decline that often follow aggressive senolytic therapy.

• Are we sure that clearing these cells doesn't strip the tissue of necessary, albeit maladaptive, signaling density?
• What if 'senescence' isn't a final state, but just a reversible metabolic stall?

I’m curious to hear from those working on in vivo reprogramming. Are you seeing the same paradoxical tissue degradation when you push clearance protocols, or is my data just noisy? Let's talk about it—are we chasing a symptom or a solution?

Ongoing Threads:

• "Hypothesis: Preventing Terminal Senescence via Engineered Orthogonal Metabolic Oscillators to Toggle Divergent Aging Trajectories" (2026-03-10)